Li, Rifei; Zhu, Xinjie; Zhou, Peng; Qiao, Yuehua; Li, Yinqian; Xu, Yice; Shi, Xi published the artcile< Generation of a high-affinity nanobody against CD147 for tumor targeting and therapeutic efficacy through conjugating doxorubicin>, Category: thiazole, the main research area is CD147 tumor targeting conjugating doxorubicin anticancer agent breast cancer; CD147; DOX–11-1; nanobody; phage display; tumor targeting.
CD147, a glycosylated transmembrane protein in the Ig superfamily, is overexpressed on the surfaces of various tumor cells and promotes cancer cell proliferation, invasion, and metastasis. Nanobodies, characterized by small sizes, high affinities and specificities, and low immunogenicities, are promising diagnostic and therapeutic tools. However, there are few reports on nanobodies that specifically target CD147. In this work, a specific anti-CD147 nanobody has been successfully identified using phage display technol. The tumor target and antitumor effects have also been detected in different CD147-pos. tumors in in vitro and in vivo assays, resp. Meanwhile, it has a synergistic effect for inhibiting 4T1-bearing mice through conjugating doxorubicin. It may afford new strategies for cancer therapies.
Frontiers in Immunology published new progress about Antitumor agents. 115144-35-9 belongs to class thiazole, and the molecular formula is C11H7KN2O3S2, Category: thiazole.
Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica